Natera Inc Cash Flow Conversion Efficiency
Natera Inc cash flow conversion efficiency. Based on the latest financial reports, Natera Inc (NTRA) has a cash flow conversion efficiency ratio of 0.030x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($54.79 Million) by net assets ($1.82 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Natera Inc (2012–2025)
Cash flow conversion efficiency of Natera Inc from 2012 to 2025. This chart illustrates how Natera Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Natera Inc stock price for real-time trading data and today's change.
Natera Inc Cash Flow Conversion Ratio Explained
Natera Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Natera Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Natera Inc ranked by their cash flow conversion efficiency. Also see NTRA market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Westinghouse Air Brake Technologies Corp
NYSE:WAB
|
0.018x |
|
ArcelorMittal SA ADR
NYSE:MT
|
0.017x |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
0.080x |
|
eBay Inc
NASDAQ:EBAY
|
0.112x |
|
Commerzbank AG
F:ZZMS
|
-0.217x |
|
Cheniere Energy Inc
NYSE MKT:LNG
|
0.124x |
|
UCB S.A. UNSP.ADR 1/2
F:UNC0
|
N/A |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
0.151x |
Annual Cash Flow Conversion Efficiency for Natera Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Natera Inc from 2012 to 2025. Review Natera Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.71 Billion | $215.30 Million | 0.126x | +10.79% |
| 2024-12-31 | $1.20 Billion | $135.66 Million | 0.113x | +135.17% |
| 2023-12-31 | $765.33 Million | $-246.96 Million | -0.323x | +47.22% |
| 2022-12-31 | $705.74 Million | $-431.50 Million | -0.611x | -19.15% |
| 2021-12-31 | $653.30 Million | $-335.24 Million | -0.513x | -36.71% |
| 2020-12-31 | $486.24 Million | $-182.51 Million | -0.375x | -64.90% |
| 2019-12-31 | $278.71 Million | $-63.44 Million | -0.228x | +89.63% |
| 2018-12-31 | $32.16 Million | $-70.58 Million | -2.195x | +42.98% |
| 2017-12-31 | $25.42 Million | $-97.83 Million | -3.849x | -453.40% |
| 2016-12-31 | $106.48 Million | $-74.05 Million | -0.695x | -239.66% |
| 2015-12-31 | $184.76 Million | $-37.83 Million | -0.205x | -234.43% |
| 2014-12-31 | $-171.34 Million | $10.49 Million | -0.061x | -143.51% |
| 2013-12-31 | $-171.51 Million | $-24.13 Million | 0.141x | +18.57% |
| 2012-12-31 | $-125.61 Million | $-14.90 Million | 0.119x | -- |
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehe… Read more